Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Clinical trial NCT07040943 · COMPLETED

Trial details

NCT number: NCT07040943
Sponsor: West China Hospital
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Refractory Malignant Solid Tumors mRNA Vaccine Interleukin

Start date: 2025-06-29
Primary completion: 2026-01-20
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.